- Open Access
Complex effects of flavopiridol on the expression of primary response genes
© Keskin et al; licensee BioMed Central Ltd. 2012
- Received: 5 December 2011
- Accepted: 29 March 2012
- Published: 29 March 2012
The Positive Transcription Elongation Factor b (P-TEFb) is a complex of Cyclin Dependent Kinase 9 (CDK9) with either cyclins T1, T2 or K. The complex phosphorylates the C-Terminal Domain of RNA polymerase II (RNAPII) and negative elongation factors, stimulating productive elongation by RNAPII, which is paused after initiation. P-TEFb is recruited downstream of the promoters of many genes, including primary response genes, upon certain stimuli. Flavopiridol (FVP) is a potent pharmacological inhibitor of CDK9 and has been used extensively in cells as a means to inhibit CDK9 activity. Inhibition of P-TEFb complexes has potential therapeutic applications.
It has been shown that Lipopolysaccharide (LPS) stimulates the recruitment of P-TEFb to Primary Response Genes (PRGs) and proposed that P-TEFb activity is required for their expression, as the CDK9 inhibitor DRB prevents localization of RNAPII in the body of these genes. We have previously determined the effects of FVP in global gene expression in a variety of cells and surprisingly observed that FVP results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Because inhibition of CDK9 activity is being evaluated in pre-clinical and clinical studies for the treatment of several pathologies, it is important to fully understand the short and long term effects of its inhibition. To this end, we determined the immediate and long-term effect of FVP in the expression of several PRGs. In exponentially growing normal human fibroblasts, the expression of several PRGs including FOS, JUNB, EGR1 and GADD45B, was rapidly and potently downregulated before they were upregulated following FVP treatment. In serum starved cells re-stimulated with serum, FVP also inhibited the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 were upregulated in the presence of FVP. Chromatin Immunoprecipitation of RNAPII revealed that EGR1 and GADD45B are transcribed at the FVP-treatment time points where their corresponding mRNAs accumulate. These results suggest a possible stress response triggered by CDK9 inhibition than ensues transcription of certain PRGs.
We have shown that certain PRGs are transcribed in the presence of FVP in a manner that might be independent of CDK9, suggesting a possible alternative mechanism for their transcription when P-TEFb kinase activity is pharmacologically inhibited. These results also show that the sensitivity to FVP is quite variable, even among PRGs.
- Primary Response genes
- Mitogenic stimuli
- RNA polymerase II
- Control of gene expression
The Positive Transcription Elongation Factor b (P-TEFb) is a complex of CDK9 and either cyclins T1, T2 or K [1–4]. P-TEFb is recruited to promoters by transcription factors and/or BRD4 where it stimulates transcriptional elongation by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNAPII) and the negative elongation factors DSIF and NELF [5–7]. Although cyclin K was first identified as a CDK9 partner, it appears to prefer CDK12 and CDK13, which also play a role in elongation . Yet, a role for cyclin K/CDK9 has been recently reported in maintaining genomic integrity [9, 10]. Recent work has lead to the proposal that CDK9 and CDK12/13 are the orthologs of yeast Bur1 and CTK1, respectively , which play distinct roles in elongation by RNAPII.
Flavopiridol (FVP) is a potent inhibitor of CDKs, with significant selectivity for CDK9, as its IC50 has been found to be about 7 times lower than that of the closest CDK IC50 reported to date . Incubation of HeLa or 293 cells for one hour with 300 nM FVP inhibits transcription by 60-70%, as measured in run-on assays [12, 13]. At a concentration of 1 μM, treatment of OCI-Ly3 cells with FVP results in rapid downregulation of genes with mRNA microarray patterns similar to those obtained with the transcriptional inhibitor Actinomycin D, and the kinetics of mRNA downregulation reflect the half life of the mRNAs measured . However, when human T98G cells and BJ-TERT fibroblasts were treated with 300 nM FVP for extended periods of time (4 to 24 h) or with a dominant form of CDK9, we observed upregulation of a very significant number of mRNAs . Among the genes that were upregulated were a number of primary response genes (PRGs). PRGs are genes that are induced in response to a variety of signals and do not require de novo protein synthesis . Our findings appeared to be at odds with recent work that has shown that expression of PRGs responsive to LPS stimulation in macrophages correlates with recruitment of cyclin T1 and CDK9 to those genes coinciding with phosphorylation of the CTD of RNAPII on Ser-2, and that preincubation of macrophages with 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB), a CDK9 inhibitor, prevents RNAPII Ser-2 phosphorylation and productive elongation of these genes .
Since inhibition of CDK9 activity is being explored as a therapeutic avenue in a number of diseases including AIDS, cancer, cardiac myopathies and inflammatory processes [11, 18–20], it is important to examine the time dependent consequences of CDK9 inhibition on gene expression. To this end, we have determined the short and long term effects of FVP treatment on the expression of PRG mRNAs and the localization of RNAPII in these genes. Our results suggest that a fraction of PRGs are transcribed in the presence of FVP, under conditions where phosphorylation of the CTD of RNAPII on Ser-2 and Ser-5 and the expression of other genes are clearly inhibited.
We have found that a large number of genes are upregulated after treating T98G cells  or hTERT-immortalized normal human fibroblasts (BJ-TERT fibroblasts) (unpublished observations) with flavopiridol (FVP) for 4 h or more. Surprisingly, some of these genes are classical PRGs. Because the normalized data set for the BJ-TERT fibroblasts study is much larger, all experiments and analyses described below were performed using BJ-TERT fibroblasts (the results of the entire BJ-TERT dataset will be reported elsewhere).
Also, genes previously defined as Immediate Response Genes (IRGs) to mitogenic stimuli  were clustered as shown in Figure 1B. In this group, most IRGs were downregulated with FVP and dnCDK9, but a significant number of "classical" IRGs such as EGR1, FOS, and CCND1, were upregulated upon FVP treatment, and in some cases by dnCDK9. Importantly, the expression profile of genes in clusters 3 and 4 of Figure 1A suggested that genes could be subject to inhibition by FVP at early time points and subsequently be upregulated, since the earliest FVP treatment time point in the microarray analysis was 4 h. Therefore, we rationalized that the genes in cluster 2 could potentially be downregulated prior to the 4 h time point collected. To test this possibility, a new set of time course experiments where BJ-TERT cells were treated with FVP for periods of time as short as 30 min was performed. The expression levels of these genes were determined by Q-RT-PCR as described in the Methods section.
Q-RT-PCR experiments validate the microarray results and unveil genes whose expression is potently and rapidly inhibited by FVP and subsequently upregulated
For this analysis we selected the following PRG-I genes; EGR1, JUNB, and FOS (Figure 1A), and the IRG Cyclin D1 (Figure 1B), which are upregulated at 8 and 24 h of FVP treatment. We also selected the IRG response gene GADD45B, which is downregulated 4 and 8 h and subsequently upregulated at 24 h (Figure 1B). In addition, we selected two genes from the microarray analyses that were downregulated at all time points: HEXIM1 and MCL1. Of note, HEXIM1 is a known CDK9 target gene  and MCL1 is an IRG . Finally, we also selected ALDOA, a housekeeping gene whose expression was found to be unchanged in the microarray analysis (Figure 1A, bottom panel).
To make the visualization of the comparison of microarray and Q-RT-PCR data clearer, Q-RT-PCR values from this experiment were converted to log2 ratios and represented with Java-TreeView with the same color gradient used in the microarray data (Figure 2B). This representation allows concise visualization and clusters the genes according to similar kinetics of expression. To compare the exact same time points in the microarray and Q-RT-PCR data, the microarray data and log2 converted Q-RT-PCR data for 4, 8, and 24 h of FVP treatment were visualized with Java-TreeView. Figure 2C demonstrates the similarity of the expression data obtained by microarray and Q-RT-PCR analysis. Next, this experiment was repeated under the same conditions, except that transduction with control adenoviruses was omitted. We found that the kinetics of downregulation/upregulation of all these genes was very similar (Additional file 2: Figure S2), indicating that viral transduction does not significantly affect the expression of these genes in BJ-TERT fibroblasts. Altogether these experiments demonstrate that several classical PRG/IRGs are rapidly downregulated but subsequently recover and are upregulated in the presence of FVP. Of note, these genes are upregulated at the same time that other genes are maximally downregulated (Figure 2B) and phosphorylation of the CTD of RNAPII on Ser-2 and Ser-5 remains inhibited (see below).
Certain PRG/IRGs are significantly expressed in the presence of FVP during a mitogenic response
First, we determined the effect of FVP upon serum stimulation of BJ-TERT cells on the cell cycle by flow cytometric analysis of propidium iodide stained cells and by western blot analysis of cell cycle markers (Figure 3A and 3B). Serum re-stimulated BJ-TERT cells exhibited 36% of cells in S phase 22 h post stimulation and cells reached the G2/M phases by 30 h. In contrast, cells re-stimulated with serum in the presence of FVP remained with a G0/G1 DNA content by 30 h. Thus, FVP completely blocked entry into S phase. For parallel western blot analysis, BJ-TERT fibroblasts were collected at additional time points as indicated. FVP inhibited expression of Cyclin D1, and completely blocked upregulation of p107, an E2F-dependent gene product. This indicates that cells are likely blocked prior to the restriction point in G1 or earlier, as passage through the restriction point is associated with activation of E2F dependent gene expression (Figure 3B) . The effects of FVP in transcription were monitored by determining the phosphorylation state of RNAPII. CDK9 is thought to phosphorylate Ser-2, while Ser-5 is thought to be phosphorylated by CDK7 and other kinases. FVP potently inhibited Ser-2 and Ser-5 phosphorylation of RNAPII within 2 h of treatment, and importantly, phosphorylation remained inhibited through the time course, which is consistent with a general block in transcription. Also, consistently with the effects of FVP on the expression of MCL1 mRNA, we observed a block on MCL1 protein upregulation and sharp downregulation below its basal levels in quiescent cells (Figure 3B). To exclude the possibility that the concentration of FVP (300 nM) used in these experiments inhibited G1 CDKs, we determined the effects of FVP at different concentrations ranging from 10 nM to 10 μM on the phosphorylation of pocket proteins (pRB, p107 and p130), as compared to RNAPII CTD phosphorylation on Ser-2 and Ser-5 (Figure 3). In agreement with our previous work, 300 nM FVP resulted in inhibition of both Ser-2 and Ser-5 phosphorylation , while dephosphorylation of pocket proteins was only noticeable at a FVP concentration of 10 μM.
Next, we performed three independent serum starvation experiments to determine the effects of FVP on the transcript levels of various PRGs. BJ-TERT fibroblasts were serum starved for three days and subsequently stimulated with serum in the presence of FVP or vehicle (DMSO). Figure 3D shows rapid and potent serum-dependent stimulation of FOS, EGR1, JUNB and GADD45B, as would be expected from any highly inducible PRG in one of these three experiments. FOS and EGR1 peak at 30 to 60 min post stimulation, while GADD45B and JUNB peak at least 30 min later. Induction of these genes is more potent for FOS that reaches up to 350 fold, being near 10-30 fold for the other PRG genes. The expression of these four genes goes back to the expression level seen in quiescent cells between 4 and 22 h of serum stimulation. MCL1 behaves similarly, peaking about 1 h, but it is only upregulated 4 to 6 fold, while CCND1 peaks later and is upregulated to a lower extent (Figure 3D).
FVP inhibits the expression of all these genes. In the case of FOS, this inhibition is extremely potent, if not complete. MCL1 and CCND1 are also clearly inhibited, and in the case of MCL1, expression goes clearly below the basal levels observed in quiescent cells. Importantly, GADD45B, JUNB and EGR1 are all induced at significant levels in the presence of FVP, although there is clear variability within the experiments (Figure 3D). GADD45B is upregulated between 5 and 17 fold by 22 h, and induction over basal levels is first seen 1 h post stimulation. JUNB is induced 4-6 fold, peaking 4 h in the presence of FVP. On the other hand, EGR1 is the most variable; its expression is completely blocked by FVP in experiment 1 (Figure 3D, left panel), but potently upregulated in experiment 2 (Figure 3D, middle panel). These results suggest that the activities inhibited by FVP, which include CDK9, are clearly important for the mitogen induced transcription program. However, these results also show that the sensitivity of genes to FVP is highly variable and that some genes can be significantly expressed in the presence of FVP, when RNAPII phosphorylation is clearly inhibited.
Some PRGs are transcribed in the presence of FVP
FVP inhibited elongation by RNAPII of FOS 15 min post serum stimulation by 2 fold, but elongation was completely blocked at 4 and 22 h (Figure 4 left panel, green bars, PS-E). Of note, RNAPII remained bound just downstream of the promoter at all times of FVP treatment, indicating that FVP does not prevent basal transcription initiation, although it eliminates the increased recruitment observed with serum (Figure 4, PS-C, compare three bars). In contrast to FOS, RNAPII is detected at all time points with PS-E of EGR1 upon FVP treatment, suggesting that EGR1 is transcriptionally elongated even in the presence of FVP. In addition, RNAPII recruitment is increased on EGR1 downstream of the promoter site at 4 and 22 h of FVP treatment (Figure 4, middle panel, green bars). GADD45B also appears to be transcriptionally elongated at 15 min, and 4 and 22 h of FVP treatment (Figure 4, right panel, green bars) but RNAPII levels are relatively much higher at 4 and 22 h of FVP treatment immediately downstream of the promoter.
In summary, FOS is transcriptionally elongated at early time points of serum stimulation but this gene is not elongated at later time points either in the presence or absence of FVP. In contrast, EGR1 and GADD45B are transcriptionally elongated at early time points upon serum stimulation; however, these genes are also transcriptionally elongated upon FVP treatment at all time points. Of note, these results are consistent with the mRNA expression effects of FVP in these genes as determined by microarray and Q-RT-PCR analysis. Considering that the expression of other genes is completely repressed and that cells treated with FVP exhibit potent inhibition of RNAPII, Ser-2 and Ser-5 phosphorylation (Figure 3B), it appears possible that both EGR1 and GADD45B posses alternative mechanisms of transcriptional elongation independent of CDK9 and other FVP-sensitive kinases.
Hierarchical clustering analysis of microarray expression ratios of select PRG/IRGs revealed that a subset of these genes were upregulated between 4 and 8 h of FVP treatment and maximally upregulated by 24 h. This at first appeared to be at odds with recently published work by Hargreaves et al (2009). The authors of this study have shown that stimulation of primary macrophages with LPS leads to rapid upregulation of a number of PRGs. They have shown that unstimulated PRGs exhibit paused RNAPII with Ser-5 phosphorylation at the promoters, but Secondary Response Genes (SRGs) do not. Their data also show that LPS stimulation leads to recruitment of CDK9 and Cyclin T1, and RNAPII with Ser-2 phosphorylation and this is blocked by DRB, a pharmacological inhibitor of CDK9. Our microarray analysis of PRG/IRGs has led to the identification of a cluster of about a third of these genes that are upregulated upon FVP treatment. This includes two classical PRGs, EGR1 and FOS that we selected for further study. Interestingly, genes in cluster 3 and 4 (Figure 1A) were found to be downregulated by 4 h of FVP treatment and subsequently upregulated, suggesting the possibility that PRGs are transiently downregulated by FVP.
Our q-RT-PCR data confirmed both the upregulation of genes in cluster 2 at late FVP time points and the hypothesis of the transient effects of FVP. In Figure 2A and 2B, it is clearly shown that EGR1, FOS, GADD45B and JUNB are rapidly downregulated by 30 min of treatment and go back to basal levels between 4 and 8 h, and then, are rapidly upregulated. One possible interpretation of these results is that FVP is at least partially metabolized in the cell, and thus, these genes are no longer inhibited. However, a number of observations argue against this possibility. First, RNAPII phosphorylation on Ser-2 and Ser-5 remains inhibited through the time course. Second, several PRG/IRGs remain inhibited through the time course. Third, genes in cluster 2 are not just going back to basal levels, but are clearly upregulated, often by several fold, under conditions in which housekeeping genes are not modulated. Fourth, previous work has shown genes that are transcribed independently of CDK9, such as certain p53 target genes  and the U2 snRNA and histone H2b genes .
To investigate this further, it was necessary to use a more defined model of primary response to stimulus. Since EGR1, FOS, JUNB and GADD45B are all responsive to serum stimulation [21, 28, 31], we selected this system. Our data clearly shows that FVP, at concentrations that do not inhibit pocket protein phosphorylation, completely blocks DNA synthesis and the upregulation of cell cycle markers, such as the expression of the E2F-dependent product p107, suggesting that cells are arrested before the restriction point in G1 or even earlier at the G0/G1 transition . This arrest is preceded by potent inhibition of total Ser-2 and Ser-5 phosphorylation on the CTD of RNAPII, which remains low throughout the time course. Under these conditions, three genes (GADD45B, JUNB and EGR1) exhibited time dependent upregulation of their expression over untreated cells in the presence of FVP. Although there was variability between experiments, the trend was similar. In contrast, FOS expression was completely blocked under these conditions. Consistent with these results, RNAPII ChIP localization assays demonstrated the presence of RNAPII in the body of the EGR1 and GADD45B genes, at 4 and 24 h of serum stimulation in the presence of FVP. In contrast, RNAPII could not be detected in the body of the FOS gene at these time points. These data strongly suggest that the upregulation of EGR1 and GADD45B expression seen in the presence of FVP is due to active transcription. Another interesting observation is the accumulation of RNAPII in chromatin downstream of the promoter near the beginning of exon 1 of EGR1 and GADD45B. This accumulation can be due to increased recruitment of RNAPII under conditions of stress (sustained inhibition of transcription), but it could also indicate increased elongation of transcripts that is not fully productive. Distinguishing between these possibilities would require further experimentation addressing the recruitment of transcription factors and the phosphorylation of RNAPII using ChIP.
Two studies published when this work was being completed have examined the effects of pharmacological inhibition of CDK9 in the expression of PRGs. In the first of these studies, FVP dramatically inhibited the expression of FOS, EGR1, EGR2 and EGR3 upon 30 min of serum stimulation of HCT116 cells . ChIP showed inhibition of RNAPII localization and diminished Ser-2 and Ser-5 phosphorylation of RNAPII in the body of the EGR1 and EGR2 genes. While this study did not determine the effects of FVP at later time points, they observed increased RNAPII at the promoter in the presence of FVP at 30 min post serum stimulation. This effect might be related to our observation of increased RNAPII near exon 1 of EGR1 gene at 4 and 24 h of serum stimulation. The second study utilized halogenated imidazole derivatives that blocked transcriptional elongation and, at least one of them, CDK9 activity . In this study, both compounds potently inhibited the transcription of PRGs. However, the study did not analyze the effects of these compounds at later time points.
Two previous studies have investigated the rapid effects of FVP on gene expression globally. Both studies used concentrations of FVP of 1 μM. This concentration of FVP is very toxic, and it is unclear if any other CTD CDKs are inhibited under these conditions. Lam et al. showed that 1 μM FVP results in the rapid downregulation of genes up to 8 h . Rahl et al. using ChIP-seq showed that 1 μM FVP completely blocks localization of RNAPII in the body of actively transcribed genes, but does not affect localization of RNAPII near the promoter . If a concentration of 1 μM FVP is selective for CDK9 inhibition in cells, these data would mean that CDK9 is essential for transcriptional elongation of a large proportion of genes. Of note, Chao and Price showed previously that FVP treatment (300 nM) of HeLa cells inhibits transcription in in vitro run on assays by 70% . Again, if 300 nM FVP selectively inhibits CDK9, these data would demonstrate that CDK9 inhibition halts transcription of most genes. This could be a direct effect on genes that require CDK9 for elongation, i.e. PRGs, and indirect on those genes not transcribed because of rapid depletion of inducible transcription factors.
Ser-2 and Ser-5 phosphorylation of the CTD of RNAPII have been linked to recruitment of histone chaperones such as Spt6 and/or histone modifications, including H3K36me3, which may play roles in nucleosome disassembly and assembly during elongation by RNAPII [32, 33]. Thus, inhibition of RNAPII Ser-2 and Ser-5 phosphorylation at certain genes may prevent nucleosome reassembly and facilitate sustained transcription with a delay.
Finally, it is also conceivable that after a potent inhibition of transcriptional elongation that quickly depletes the cell from PRG/IRGs and other highly inducible transcription factors, the cell might require a boost in the expression of some of these PRG/IRGs. Gene expression might differentially oscillate before reaching a new transcriptional equilibrium. Some gene expression oscillation might be CDK9 independent, occurring while CDK9 is still effectively inhibited. Other changes might follow the expression of required PRG transcription factors. Understanding this fully will require more extensive studies using ChIP and/or ChIP-seq for RNAPII phosphorylated on Ser-2 and Ser-5, as well as recruitment of CDK9 and other RNAPII CDKs using FVP and more selective inhibitors of CDK9. Future gene expression profiling experiments should include short treatments with pharmacological inhibitors of CDK9. This will allow more precise identification of the groups of genes that are co-modulated in a time dependent manner.
Understanding the effects of CDK9 inhibition on gene expression is of considerable interest because of therapeutic implications. CDK9/Cyclin T1 activity is essential for HIV transcription, and hence, replication [1, 13, 34–37]. CDK9 activity is upregulated in hypertrophic cardiomyopathy . Moreover, Mixed Lineage Leukemia  and certain ER-positive breast cancer [40, 41] exhibit deregulation of P-TEFb activity. Thus, understanding the consequences of inhibiting CDK9 activity on gene expression over time is important. Our data suggest the possibility of a stress response to the effects of inhibiting transcriptional elongation that may result in the transcription of certain genes in a CDK9 independent manner. Some of the genes that would fit this category would be the PRG/IRG EGR1 and GADD45B, but the members of PRG/IRGs behaving in this manner are like to be larger.
We have shown that certain PRGs are transcribed in the presence of FVP in a manner that appears independent of CDK9 suggesting the existence of a possible alternative mechanism for their transcription when P-TEFb kinase activity is pharmacologically inhibited. This could be part of a stress response to the effects of inhibiting transcriptional elongation. Understanding the effects of CDK9 inhibition on gene expression over time is of considerable interest because it is a potential therapeutic target in a number of diseases including AIDS, certain cancers, inflammatory processes and hypertrophic cardiomyopathy.
Cell culture and treatments
Human BJ-TERT fibroblasts are normal BJ fibroblasts immortalized with human Telomerase Reserve Transcriptase (hTERT) . BJ-TERT fibroblasts were maintained in Dulbecco's Modification of Eagle's Medium (DMEM) (Cellgro) supplemented with 10% Fetal Bovine Serum (FBS) (Gemini) and 100 U/ml penicillin and 100 μg/ml streptomycin (Gemini). Cells were grown at 37°C in 5% CO2. For primary response gene assays, BJ-TERT fibroblasts were grown up to 50-70% confluence and starved in serum-free medium for 72 h as described in . CDK9 was pharmacologically inhibited by adding Flavopiridol (FVP). FVP was prepared in DMSO at a concentration of 10 mM then dissolved in PBS to 100 μM and added to the medium to give a final concentration of 300 nM. Control cells were treated with the same concentration of DMSO (Dimethyl sulfoxide) dissolved in PBS. Thirty minutes after the addition of FVP or DMSO, serum starved cells were stimulated with serum and collected at the times indicated in the results section. Flow cytometric cell cycle analysis was done as previously described . Where indicated, FVP treated cells were preinfected with control adenoviruses Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™ in the presence of tetracyclin (dn + tet) to eliminate viral transduction as a variable in the comparison to dnCDK9 expressing cells (transduced with Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™ in the absence of tetracyclin (dn)). BJ-TERT fibroblasts were infected with Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™ adenviruses (dn) in the presence or absence of tetracyclin (tet) essentialy as previously descrived  and then treated with FVP for the times indicated in the figures.
Cells were lysed with ice-cold lysis buffer (50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton X-100, 0.1 mM Na3VO4, 2 mM PMSF, 10 μg/ml leupeptin, 4 μg/ml aprotinin, and 40 μg/ml pepstanin). Proteins were resolved by 8% polyacrylamide/SDS gel electrophoresis, and transferred to a polyvinylidene difluoride (PVDF) membrane (Immobilon-FL, Millipore) in 10 mM CAPS/10% methanol buffer (pH 11). Western blot analyses were performed as described previously . Bands were visualized by using Western Lighting Plus ECL reagent (Perkin Elmer) and X-Ray film or imaging with FluorChemQ Imaging System (Alpha Innotech). For Western blot analyses the following antibodies were used: Anti-RNAPII (A300-653A), anti-Ser-2 (A300-654A), and anti-Ser-5 (A300-655A) rabbit polyclonal antibodies were obtained from Bethyl. Anti-MCL1 (sc-819), anti-Cyclin D1 (sc-8396), anti-CDK2 (sc-163), anti-Cyclin E (sc-481), and anti-p107 (sc-318) rabbit polyclonal antibodies were obtained from Santa Cruz Biotechnology.
Microarray cluster analysis
The Affymetrix Human Gene 1.0 ST transcript data set utilized in the cluster analysis described in this report will be reported elsewhere. Hierarchical cluster analysis (Cluster version 3.0, ) was performed to cluster genes using average linkage clustering and visualized with Java TreeView, version 1.0.13 as in .
Q-RT-PCR and Q-PCR
RNA was isolated from BJ-TERT fibroblasts by using the RNeasy Extraction Kit (Qiagen). RNA expression was determined in 96 well plates using the TaqMan 1 Step PCR Kit (Applied Biosystems) and 20 μl reactions containing specific TaqMan probes. mRNA levels were determined using an ABI Prism 7000 RT-PCR system (Applied Biosystems). Taqman probes used in this study are as follow: JUNB (Hs00357891_s1), ALDOA (Hs00605108_g1), HEXIM1 (Hs0053918_s1), GADD45B (Hs00169387_m1), CCND1 (Hs99999004_m1), MCL1 (Hs03043899_m1), FOS (Hs01119256_g1), EGR1 (Hs00152928_m1). A GAPDH probe was used for normalization. Threshold Cycle (CT) values for each sample were normalized with GAPDH CT values. Then, a second normalization was performed by subtracting normalized values of each time point from the control normalized value per each gene.
SYBR Green qPCR Mix (Fermentas) was used to determine relative DNA amounts in input chromatin samples and ChIPs (anti-RNAPII) and IP mock (IgG) in 96 well plates using the StepOnePlus PCR instrument (Applied Biosystems). RNAPII IP and mock ChIP CT values were normalized with input CT values to obtain the percentage of input values separately for each primer set. The percentage of input was calculated, mock ChIP values were subtracted from RNAPII ChIP values and results were visualized via Excel graphs.
Additional file 3: Table S1 shows primers for FOS and EGR1 (Donner, et al, 2010), and GADD45B genes. The Reference Sequence (RefSeq) of human GADD45B was obtained from ECR browser http://ecrbrowser.dcode.org. Four different primer pairs were designed using Oligo Perfect™ Designer http://www.invitrogen.com to amplify the following sequences: Primer set A: upstream of the gene; Primer set C: 5'UTR close to Exon 1; Primer set E: Exon 3; Primer set H: downstream of the gene.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were carried out as described in . BJ-TERT fibroblasts were grown in 10 cm plates up to 50-70% confluence. Serum-starved cells were treated with FVP or DMSO, and then stimulated with serum as described in the cell culture section. Cells were fixed with 1% formaldehyde/PBS for 15 min at room temperature. The cross-linking reaction was stopped by adding glycine (0.125 M). Cells were then washed twice with cold PBS, and harvested with complete Szak's RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8, 5 mM EDTA, Protease Inhibitor Cocktail (Roche), 10 mM PMSF). Cells were then sonicated for 30 cycles of 15 s, followed by 1 min rest on ice (50% duty cycle). Sonicated chromatin was cleared by centrifugation. The amount of protein in the cell was quantified by using the BCA Protein assay kit (Thermo Scientific). Sonicated DNA was about 300 bp. Sheared chromatin extracts were pre-cleared with Protein A sepharose beads. Protein A beads loaded with antibodies and blocked with BSA and Salmon Sperm DNA were incubated with chromatin overnight at 4°C on a rotator. The immunoprecipitated chromatin was washed twice with incomplete RIPA buffer (without PMSF and Protease Inhibitor cocktail), four times with Szak IP Wash Buffer (100 mM Tris HCl pH 8.5, 500 mM LiCl, 1% Nonidet P-40, 1% deoxycholate), then twice again with incomplete RIPA buffer and twice with cold 1X TE. The cross-links were then reversed by adding Talianidis Elution Buffer (1.5X) (70 mM Tris HCl pH 8, 1 mM EDTA, 1.5% SDS), and NaCl (200 mM final) overnight at 65°C. Samples were then treated with 20 μg of Proteinase K (Qiagen) for 30 min at 45°C, extracted with Phenol/Chloroform and ethanol precipitated. The pellet was resuspended in water and analyzed by Q-PCR as described above. The following antibodies were used for ChIP: Anti-RNAPII (8WG16) monoclonal antibodies from Covance and mouse monoclonal IgGs (sc-2025) from Santa Cruz Biotechnology.
We thank Aaron J Donner and Joaquín Espinosa for advise and helpful discussions, and Alison Kurimchak for critically reading the manuscript. This work was supported, in whole or in part, by National Institutes of Health Grant MH083585 to XG. This work was also supported by a grant from the Pennsylvania Department of Health to X.G. HK was supported by a fellowship from the Ministry of Science of Turkey.
- Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998, 92: 451–462. 10.1016/S0092-8674(00)80939-3View ArticlePubMedGoogle Scholar
- Peng J, Marshall NF, Price DH: Identification of a cyclin subunit required for the function of Drosophila P-TEFb. J Biol Chem 1998, 273: 13855–13860. 10.1074/jbc.273.22.13855View ArticlePubMedGoogle Scholar
- Peng J, Zhu Y, Milton JT, Price DH: Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 1998, 12: 755–762. 10.1101/gad.12.5.755PubMed CentralView ArticlePubMedGoogle Scholar
- Fu TJ, Peng J, Lee G, Price DH, Flores O: Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription. J Biol Chem 1999, 274: 34527–34530. 10.1074/jbc.274.49.34527View ArticlePubMedGoogle Scholar
- Garriga J, Graña X: Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004, 337: 15–23.View ArticlePubMedGoogle Scholar
- Marshall RM, Graña X: Mechanisms controlling CDK9 activity. Front Biosci 2006, 11: 2598–2613. 10.2741/1994View ArticlePubMedGoogle Scholar
- Kohoutek J: P-TEFb--the final frontier. Cell Div 2009, 4: 19. 10.1186/1747-1028-4-19PubMed CentralView ArticlePubMedGoogle Scholar
- Bartkowiak B, Liu P, Phatnani HP, Fuda NJ, Cooper JJ, Price DH, Adelman K, Lis JT, Greenleaf AL: CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev 2010, 24: 2303–2316. 10.1101/gad.1968210PubMed CentralView ArticlePubMedGoogle Scholar
- Yu DS, Cortez D: A role for cdk9-cyclin k in maintaining genome integrity. Cell Cycle 2011, 10: 28–32. 10.4161/cc.10.1.14364PubMed CentralView ArticlePubMedGoogle Scholar
- Yu DS, Zhao R, Hsu EL, Cayer J, Ye F, Guo Y, Shyr Y, Cortez D: Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep 2010, 11: 876–882. 10.1038/embor.2010.153PubMed CentralView ArticlePubMedGoogle Scholar
- Klebl B, Choidas A: CDK9/cyclin T1: a host cell target for antiretroviral therapy. Futur Virol 2006, 1: 317–330. 10.2217/174607184.108.40.2067View ArticleGoogle Scholar
- Chao SH, Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001, 276: 31793–31799. 10.1074/jbc.M102306200View ArticlePubMedGoogle Scholar
- Salerno D, Hasham MG, Marshall R, Garriga J, Tsygankov AY, Grana X: Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene 2007, 405: 65–78. 10.1016/j.gene.2007.09.010PubMed CentralView ArticlePubMedGoogle Scholar
- Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, et al.: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001., 2: RESEARCH0041Google Scholar
- Garriga J, Xie H, Obradovic Z, Grana X: Selective control of gene expression by CDK9 in human cells. J Cell Physiol 2010, 222: 200–208. 10.1002/jcp.21938PubMed CentralView ArticlePubMedGoogle Scholar
- Fowler T, Sen R, Roy AL: Regulation of primary response genes. Mol Cell 2011, 44: 348–360. 10.1016/j.molcel.2011.09.014PubMed CentralView ArticlePubMedGoogle Scholar
- Hargreaves DC, Horng T, Medzhitov R: Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009, 138: 129–145. 10.1016/j.cell.2009.05.047PubMed CentralView ArticlePubMedGoogle Scholar
- Krystof V, Chamrad I, Jorda R, Kohoutek J: Pharmacological targeting of CDK9 in cardiac hypertrophy. Med Res Rev 2010, 30: 646–666.PubMedGoogle Scholar
- Wang S, Fischer PM: Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008, 29: 302–313. 10.1016/j.tips.2008.03.003View ArticlePubMedGoogle Scholar
- Brasier AR: Expanding role of cyclin dependent kinases in cytokine inducible gene expression. Cell Cycle 2008, 7: 2661–2666. 10.4161/cc.7.17.6594PubMed CentralView ArticlePubMedGoogle Scholar
- Tullai JW, Schaffer ME, Mullenbrock S, Sholder G, Kasif S, Cooper GM: Immediate-early and delayed primary response genes are distinct in function and genomic architecture. J Biol Chem 2007, 282: 23981–23995. 10.1074/jbc.M702044200PubMed CentralView ArticlePubMedGoogle Scholar
- He N, Pezda AC, Zhou Q: Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol 2006, 26: 7068–7076. 10.1128/MCB.00778-06PubMed CentralView ArticlePubMedGoogle Scholar
- Sotillo E, Graña X: Escape from cellular quiescence. In In Cell Cycle Deregulation in Cancer, Contemporary Cancer Research. Edited by: Enders GH, Nickoloff JA. Springer New York Dordrecht Heidelberg London; 2010:3–22. Springer PublishingView ArticleGoogle Scholar
- Zeitlinger J, Stark A, Kellis M, Hong JW, Nechaev S, Adelman K, Levine M, Young RA: RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo. Nat Genet 2007, 39: 1512–1516. 10.1038/ng.2007.26PubMed CentralView ArticlePubMedGoogle Scholar
- Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA: A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007, 130: 77–88. 10.1016/j.cell.2007.05.042PubMed CentralView ArticlePubMedGoogle Scholar
- Muse GW, Gilchrist DA, Nechaev S, Shah R, Parker JS, Grissom SF, Zeitlinger J, Adelman K: RNA polymerase is poised for activation across the genome. Nat Genet 2007, 39: 1507–1511. 10.1038/ng.2007.21PubMed CentralView ArticlePubMedGoogle Scholar
- Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA: c-Myc regulates transcriptional pause release. Cell 2010, 141: 432–445. 10.1016/j.cell.2010.03.030PubMed CentralView ArticlePubMedGoogle Scholar
- Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM: CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat Struct Mol Biol 2010, 17: 194–201. 10.1038/nsmb.1752PubMed CentralView ArticlePubMedGoogle Scholar
- Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM: Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 2006, 20: 601–612. 10.1101/gad.1398206PubMed CentralView ArticlePubMedGoogle Scholar
- Medlin J, Scurry A, Taylor A, Zhang F, Peterlin BM, Murphy S: P-TEFb is not an essential elongation factor for the intronless human U2 snRNA and histone H2b genes. EMBO J 2005, 24: 4154–4165. 10.1038/sj.emboj.7600876PubMed CentralView ArticlePubMedGoogle Scholar
- Mikula M, Hanusek K, Paziewska A, Dzwonek A, Rubel T, Bomsztyk K, Ostrowski J: Halogenated imidazole derivatives block RNA polymerase II elongation along mitogen inducible genes. BMC Mol Biol 2010, 11: 4. 10.1186/1471-2199-11-4PubMed CentralView ArticlePubMedGoogle Scholar
- Yoh SM, Cho H, Pickle L, Evans RM, Jones KA: The Spt6 SH2 domain binds Ser2-P RNAPII to direct Iws1-dependent mRNA splicing and export. Genes Dev 2007, 21: 160–174. 10.1101/gad.1503107PubMed CentralView ArticlePubMedGoogle Scholar
- Bres V, Yoh SM, Jones KA: The multi-tasking P-TEFb complex. Curr Opin Cell Biol 2008, 20: 334–340. 10.1016/j.ceb.2008.04.008PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH: Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997, 11: 2622–2632. 10.1101/gad.11.20.2622PubMed CentralView ArticlePubMedGoogle Scholar
- Yang X, Gold MO, Tang DN, Lewis DE, Aguilar-Cordova E, Rice AP, Herrmann CH: TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci USA 1997, 94: 12331–12336. 10.1073/pnas.94.23.12331PubMed CentralView ArticlePubMedGoogle Scholar
- Flores O, Lee G, Kessler J, Miller M, Schlief W, Tomassini J, Hazuda D: Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Proc Natl Acad Sci USA 1999, 96: 7208–7213. 10.1073/pnas.96.13.7208PubMed CentralView ArticlePubMedGoogle Scholar
- Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000, 275: 28345–28348.View ArticlePubMedGoogle Scholar
- Sano M, Schneider MD: Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ Res 2004, 95: 867–876. 10.1161/01.RES.0000146675.88354.04View ArticlePubMedGoogle Scholar
- Smith E, Lin C, Shilatifard A: The super elongation complex (SEC) and MLL in development and disease. Genes Dev 2011, 25: 661–672. 10.1101/gad.2015411PubMed CentralView ArticlePubMedGoogle Scholar
- Ketchart W, Ogba N, Kresak A, Albert JM, Pink JJ, Montano MM: HEXIM1 is a critical determinant of the response to tamoxifen. Oncogene 2011, 30: 3563–3569. 10.1038/onc.2011.76PubMed CentralView ArticlePubMedGoogle Scholar
- Ogba N, Chaplin LJ, Doughman YQ, Fujinaga K, Montano MM: HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb. Cancer Res 2008, 68: 7015–7024. 10.1158/0008-5472.CAN-08-0814PubMed CentralView ArticlePubMedGoogle Scholar
- Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature 1999, 400: 464–468. 10.1038/22780View ArticlePubMedGoogle Scholar
- Sotillo E, Garriga J, Kurimchak A, Grana X: Cyclin E and SV40 small T antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. J Biol Chem 2008, 283: 11280–11292. 10.1074/jbc.M709055200PubMed CentralView ArticlePubMedGoogle Scholar
- Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95: 14863–14868. 10.1073/pnas.95.25.14863PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.